

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (PREVIOUSLY PRESENTED) A method of replenishing human growth hormone (hGH) in an adult human comprising administering a composition consisting essentially of recombinant hGH in an individualized dose to replenish hGH, said individualized dose determined by

(1) determining a response of said human to an initial dose of said composition administered on a daily basis,

(2) thereafter determining a response of said human to serially increased doses of said composition administered on a daily basis,

(3) selecting said dose of composition from (2) producing an optimal replenishment to administer as a maintenance dose, and

(4) thereafter administering said dose from (3) to replenish hGH.

2. (PREVIOUSLY PRESENTED) The method of claim 1 wherein said maintenance dose is calculated from a daily dose to a monthly dose based on individualized bioavailability data and is administered monthly.

3. (ORIGINAL) The method of claim 2 wherein said dose comprises a microsphere formulation of said agent.

4. CANCELED.

5. (ORIGINAL) The method of claim 1 wherein said human is a male and said maintenance dose is in the range of about 10-14  $\mu\text{g/kg/day}$ .

6. (ORIGINAL) The method of claim 1 wherein said human is a female and said maintenance dose is in the range of about 14-20  $\mu\text{g/kg/day}$ .

7. (PREVIOUSLY PRESENTED) The method of claim 1 wherein said response comprises increased insulin like growth factor-1 levels.

8. (ORIGINAL) The method of claim 1 wherein said human is a male and said initial dose is about 2  $\mu\text{g/kg/day}$ .

9. (ORIGINAL) The method of claim 1 wherein said human is a female and said initial dose is about 4  $\mu\text{g/kg/day}$ .

10. (CURRENTLY AMENDED) A method of providing an adult human with human growth hormone (hGH) comprising

administering a composition consisting essentially of recombinant hGH to said human on a daily basis at an initial dose to produce an initial response to said composition,

thereafter administering at least one serially increased initial dose of said composition on a daily basis and evaluating said human's response to said serially increased dose to produce an individualized optimal response to said composition, and

thereafter administering said dose producing said optimal response as a maintenance dose.

11. (PREVIOUSLY PRESENTED) The method of claim 10 wherein said dose producing said optimal response is calculated from a daily dose to a monthly dose based on individualized bioavailability data and is administered monthly.

12. CANCELED.

13. (PREVIOUSLY PRESENTED) The method of claim 10 wherein said response is evaluated by evaluating a level of insulin like growth factor-1.

14. (ORIGINAL) A method of optimizing human growth hormone (hGH) replacement in an adult human comprising

(1) administering an initial dose of hGH in the range of about 2  $\mu\text{g/kg/day}$  hGH to about 4  $\mu\text{g/kg/day}$  on a daily basis for about three to four weeks and determining insulin like growth factor 1 (IGF-1) levels,

(2) thereafter administering serially increasing doses of said initial hGH dose on a daily basis for about three to four weeks and determining IGF-1 levels,

(3) selecting said hGH dose from (2) producing optimal hGH replenishment to administer as a maintenance dose, and

(4) thereafter administering said maintenance dose in the range of about 10  $\mu\text{g/kg/day}$  hGH to about 20  $\mu\text{g/kg/day}$  hGH to said individual.

15. (PREVIOUSLY PRESENTED) The method of claim 14 wherein said maintenance dose is calculated from a daily dose to a monthly dose based on individualized bioavailability data and is administered monthly.

16. (ORIGINAL) The method of claim 15 wherein said maintenance dose comprises hGH formulated in microspheres.

17-19. CANCELED.